Sanofi Asks Thailand To Review Compulsory Licensing Policy
This article was originally published in PharmAsia News
Executive Summary
Sanofi-Aventis sent a request to the previous Thai Minister of Commerce Mingkwan Sangsuwan to review the process of compulsory licensing on patented drugs, Graham Almond, Sanofi-Aventis Thailand general manager told PharmAsia News.
You may also be interested in...
Thailand Probes Compulsory License Clopidogrel Purchasing Woes
Thailand’s Government Pharmaceutical Organization has faced heat from the health ministry over its attempts to buy blood thinner clopidogrel under a compulsory license issued for Sanofi’s Plavix in 2007. The issue is at the heart of the country’s attempts to provide universal health care without costs spiraling out of control.
Thailand Probes Compulsory License Clopidogrel Purchasing Woes
Thailand’s Government Pharmaceutical Organization has faced heat from the health ministry over its attempts to buy blood thinner clopidogrel under a compulsory license issued for Sanofi’s Plavix in 2007. The issue is at the heart of the country’s attempts to provide universal health care without costs spiraling out of control.
Is Sobering Tone On India IP Laws An Early Signal Of Reconciliation By U.S.?
Some lawyers say views on India’s patent laws may be softening despite India winding up again on the U.S. Priority Watch List.